北京植德律师事务所 关于江苏华兰药用新材料股份有限公司 控股股东增持公司股份的 法律意见书 法律意见书 植德(证)字[2026]0007-1 号 二〇二六年二月 北京植德律师事务所 Merits & Tree Law Offices 北京市东城区东直门南大街1号来福士中心办公楼 12 层 | 邮编:100007 12th Floor, Raffles City Beijing Office Tower, No.1 Dongzhimen South Street, Dongcheng District, Beijing 100007 P.R.C 电话(Tel):010-56500900 传真(Fax):010-56500999 www.meritsandtree.com 北京植德律师事务所 关于江苏华兰药用新材料股份有限公司 控股股东增持公司股份的 植德(证)字[2026]0007-1 号 致:江阴华兰机电科技有限公司 根据本所与江阴华兰机电科技有限公司(以下简称"华兰机电"、"增持人") 签署的《律师服务协议书》,本所接受华兰机电的委托,就华兰机电自 2025 年 11月6日至 2026年2月10日内(以下简 ...

证券代码：301093 证券简称：华兰股份 公告编号：2026-015 江苏华兰药用新材料股份有限公司 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 江苏华兰药用新材料股份有限公司（以下简称"公司"或"华兰股份"）于 近日收到控股股东江阴华兰机电科技有限公司（以下简称"华兰机电"或"增 持人"）出具的《关于股份增持计划实施完成的告知函》及北京植德律师事务所 出具的《北京植德律师事务所关于江苏华兰药用新材料股份有限公司控股股东 增持公司股份的法律意见书》。公司获悉华兰机电本次增持计划已实施完成，其 于 2025 年 11 月 6 日至 2026 年 2 月 10 日通过集中竞价交易方式累计增持公司 股份 395,500 股，占公司总股本 164,201,624 股的 0.24%，占公司有表决权总数 （剔除存放于公司回购专用证券账户的 101,329 股）的 0.24%，最高成交价格为 85.730 元 / 股 ， 最 低 成 交 价 格 为 75.320 元 / 股 ， 累 计 增 持 金 额 为 人 民 币 30,023,711.000 元（不含交易费用），已超过本次增持 ...

Summary of the Conference Call on Hualan's AI Pharmaceutical Developments Company and Industry Overview - **Company**: Hualan Co., Ltd. (华兰股份) - **Industry**: AI Pharmaceutical Development - **Context**: The conference call was organized by Tianfeng Securities and several other brokerages to discuss Hualan's recent developments in the AI pharmaceutical sector, particularly its collaboration with various experts and companies in the field [1][2]. Key Points and Arguments Hualan's Background and Business Model - Hualan has over 30 years of experience and was listed in 2021, primarily known for its medical rubber products [3]. - The company has a stable revenue and profit stream, with a strong customer base of over 1,000 pharmaceutical companies, many of which have long-term relationships spanning 20-30 years [4]. - Hualan has completed capacity construction for new products and has a solid cash flow, which supports its entry into AI pharmaceuticals [5]. AI Pharmaceutical Strategy - Hualan's strategy involves leveraging its extensive customer base to support AI pharmaceutical initiatives, aiming to reduce time and costs for technology teams to connect with clients [6]. - The company plans to open its customer resource pool to all teams joining Hualan, enhancing collaboration and trust with clients [6]. Internal and External Development - Hualan has established an expert committee to guide its AI pharmaceutical direction, focusing on internal incubation and external investments [9][10]. - The company is developing four main areas: knowledge graph, small molecules, antibodies, and small nucleic acids, with a focus on mature and validated technologies [10]. Collaboration with Kema Bio - Hualan has invested in Kema Bio, which focuses on antibody design and optimization, emphasizing the importance of data accumulation and model optimization for effective drug development [12][13]. - Kema Bio's approach is to optimize models for specific targets, such as GPCRs, and to enhance the specificity and efficacy of antibodies [13][16]. Knowledge Graph Development - Hualan's knowledge graph initiative aims to structure and visualize relationships between various biological entities, enhancing drug repurposing and safety monitoring [19][20]. - The knowledge graph will facilitate the identification of new indications for existing drugs, potentially shortening development timelines [22][23]. Future Goals and Market Positioning - Hualan aims to position its AI pharmaceutical business on par with its core rubber product business, with a goal to exceed current performance levels within 3-5 years [43][44]. - The company is focused on integrating AI capabilities with existing operations to enhance service offerings and customer engagement [44]. Additional Important Content - The conference highlighted the importance of collaboration with top-tier experts and the establishment of a robust technological foundation for future developments [9][10]. - Hualan's commitment to maintaining high standards in its AI pharmaceutical initiatives was emphasized, with specific performance milestones set for the knowledge graph team [46]. - The call also addressed the competitive landscape and the need for high-quality knowledge graphs to gain market acceptance [33][34]. This summary encapsulates the key discussions and strategic directions outlined during the conference call, reflecting Hualan's ambitions in the AI pharmaceutical sector and its operational synergies.

经济观察网华兰股份（301093）董事崔珂和姚茗芳在2026年2月9日董事会审议设立AI医药孙公司议案 时投下反对票。其理由主要基于可行性担忧、治理与风控要求以及法律约束力完善等方面。值得注意的 是，两位董事均长期任职于华夏久盈资产管理有限责任公司，而华夏久盈的关联方瑞众人寿是华兰股份 的重要机构投资者(持股16.38%)。有分析认为，其反对票可能反映了该主要股东对公司跨界进入技术密 集型的AI医药领域所持的审慎态度。 以上内容基于公开资料整理，不构成投资建议。 ...

Core Viewpoint - Hualan Co., Ltd. is expanding its presence in the "AI + Medicine" sector through the establishment of a joint venture focused on drug repurposing and pharmacovigilance services, leveraging knowledge graphs and advanced technology partnerships [1][3][4] Group 1: Company Developments - Hualan Co., Ltd. has established a subsidiary, Hainan Lingqing Intelligent Pharmaceutical Technology Co., Ltd. (Lingqing Intelligent), to explore AI applications in the pharmaceutical industry [1][6] - The company plans to collaborate with a technical team led by former CTO of Insilico LLC, Yu Kaixian, and Academician Liu Jun to set up a joint venture that will focus on intelligent solutions for drug development and safety management [3][4] - The joint venture will be controlled by Lingqing Intelligent and aims to integrate heterogeneous data sources to enhance drug research and safety management [3][5] Group 2: Investment Strategy - Hualan Co., Ltd. has made significant investments in AI pharmaceutical companies, including a recent capital increase of 450 million yuan to Lingqing Intelligent, raising its registered capital to 500 million yuan [6][7] - The company is also establishing an AI Pharmaceutical Expert Committee to provide strategic planning and technical guidance for its AI-related business [7] Group 3: Market Context and Challenges - The AI pharmaceutical sector is characterized by high technical barriers and requires substantial investment in computing power, funding, and talent, which may pose operational pressures for companies with insufficient technical accumulation [5][9] - Despite the potential for efficiency gains in drug repurposing and pharmacovigilance, the competitive landscape is challenging, with established players having a head start [5][10] Group 4: Board Concerns - Two board members, Cui Ke and Yao Mingfang, opposed the establishment of the joint venture, citing the need for thorough feasibility assessments and governance structures to ensure efficient use of funds and sustainable development [9][10] - Their concerns reflect a cautious approach to the company's foray into the AI pharmaceutical field, emphasizing the importance of evaluating key factors such as data sources and commercialization pathways [10]

自去年设立子公司海南灵擎数智医药科技有限公司（以下简称"灵擎数智"）以来，注射剂类药品包装材料生产商华兰股份（301093）在"AI+医药"领域频频 落子。 华兰股份最新公告显示，灵擎数智拟与美国Insilicom LLC前首席技术官俞开先及美国科学院院士LIU JUN（刘军）领衔的技术团队开展合作，拟共同出资设 立一家合资公司，聚焦于以知识图谱为核心的药物重定向与药物警戒相关服务。而在此之前，华兰股份已陆续祭出投资AI制药企业、增资灵擎数智以及下 设AI医药专家委员会等举措。 近年来，"AI+"无疑是最具吸引力的增长叙事之一。从药品包装材料到"AI+医药"，华兰股份的转型跨度不可谓不大。不过，AI医药研发具备较高技术壁 垒，也容易面临投入大、产出慢的经营压力。不管是彼时设立灵擎数智，还是此次拟设立合资公司，华兰股份两名董事崔珂、姚茗芳均投下反对票。 拟设立孙公司加码"AI+医药" 华兰股份再度加码"AI+医药"领域。公司最新公告显示，公司全资子公司灵擎数智与俞开先、刘军领衔的技术团队开展合作，即灵擎数智、持股平台1（将 由灵擎数智与俞开先所控制的公司共同出资设立）、持股平台2（将由俞开先所控制的公司与刘军共 ...

公告提到，合资公司拟聚焦于以知识图谱为核心的药物重定向与药物警戒相关服务，通过整合多源异构 数据，为药物研发与安全管理提供智能化解决方案，具体经营范围以工商登记信息为准。 为充分激发合资公司核心技术人员及经营团队的积极性，增强合资公司长期发展动力，促进合资公司业 务目标实现，公司拟同意合资公司在一定条件下实施与业绩目标挂钩的合伙份额激励安排，即通过持股 平台1转让合伙份额实施对核心人员及其他对合资公司发展作出重要贡献人员的激励。通过将合资公司 部分权益与明确、可量化的经营业绩目标相挂钩，促使核心人员在承担经营风险的同时分享长期发展成 果，有助于实现风险共担、利益绑定、长期激励，符合合资公司实际经营需要。截至本公告披露日，灵 擎数智已与俞开先、LIUJUN（刘军）签署了《合资协议》。 近日，华兰股份发布公告称，董事会同意公司全资子公司海南灵擎数智医药科技有限公司（在本公告里 简称"灵擎数智"）与InsilicomLLC前首席技术官俞开先（CTO）及美国科学院院士LIUJUN（刘军）领 衔的技术团队开展合作，即灵擎数智、持股平台1（将由灵擎数智与俞开先所控制的公司共同出资设 立）、持股平台2【将由俞开先所控制的公 ...

格隆汇2月9日丨华兰股份(301093.SZ)公布，董事会同意公司全资子公司海南灵擎数智医药科技有限公 司（在本公告里简称"灵擎数智"）与美国Insilicom LLC前首席技术官俞开先先生（CTO）及美国科学院 院士LIU JUN（刘军）先生领衔的技术团队开展合作，即灵擎数智、持股平台1（将由灵擎数智与俞开 先所控制的公司共同出资设立）、持股平台2【将由俞开先所控制的公司与LIU JUN（刘军）共同出资 设立】拟以自有资金共同出资设立一家合资公司。其中，灵擎数智控股合资公司，合资公司将纳入公司 合并报表范围。 合资公司拟聚焦于以知识图谱为核心的药物重定向与药物警戒相关服务，通过整合多源异构数据，为药 物研发与安全管理提供智能化解决方案，具体经营范围以工商登记信息为准。 ...

华兰股份公告，全资子公司海南灵擎数智医药科技有限公司拟与美国Insilicom LLC前首席技术官俞开先 及美国科学院院士LIU JUN（刘军）领衔的技术团队共同出资设立合资公司，其中灵擎数智出资600万 元，持股60%。合资公司聚焦以知识图谱为核心的药物重定向与药物警戒相关服务，旨在探索 人工智 能技术在医药研发与药物安全管理领域的应用场景。 ...

每经头条（nbdtoutiao）——美国名校毕业刚回国，26岁"金少"空降成董事长和总经理，父母隐退！A股 多位"00后"执掌要职，"不负投资者"成重大考验 （记者 曾健辉） 每经AI快讯，华兰股份2月9日晚间发布公告称，公司第六届第十三次董事会会议于2026年2月6日以现 场会议结合通讯形式召开。会议审议了《关于全资子公司投资设立控股孙公司的议案》等文件。 ...